Keywords: curagen, revenues, climb, corp, says, ended, december
CuraGen revenues climb 38%
Article | 26 January 2001
CuraGen Corp says that for the year ended December 31, 2000, revenuesincreased 38% to $20.8 million, while net loss for 2000 was just under $27 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
